Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel A Burdmann

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
Kidney International|January 15, 2022
A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumorsVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 25, 2023
A Prospective Cross-Sectional Study on the Performance of the 2021 CKD-EPI Equations Without Race in a Multiracial Population of Adults With Solid Tumors in BrazilVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 27, 2024
Glomerular Filtration Rate Estimation Using β<sub>2</sub>-Microglobulin and β-Trace Protein in Adults With Solid Tumors: A Prospective Cross-Sectional StudyVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
Lancet (London, England)|March 18, 2015
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrologyRavindra L Mehta, Jorge Cerdá, Emmanuel A Burdmann, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2012
Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP WorkgroupMarc Ghannoum, Thomas D Nolin, David S Goldfarb, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
Kidney International|January 15, 2022
A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumorsVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 25, 2023
A Prospective Cross-Sectional Study on the Performance of the 2021 CKD-EPI Equations Without Race in a Multiracial Population of Adults With Solid Tumors in BrazilVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 27, 2024
Glomerular Filtration Rate Estimation Using β<sub>2</sub>-Microglobulin and β-Trace Protein in Adults With Solid Tumors: A Prospective Cross-Sectional StudyVerônica T Costa E Silva, Luiz A Gil, Lesley A Inker, et al.
Lancet (London, England)|March 18, 2015
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrologyRavindra L Mehta, Jorge Cerdá, Emmanuel A Burdmann, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 28, 2012
Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP WorkgroupMarc Ghannoum, Thomas D Nolin, David S Goldfarb, et al.
Pageof 15